Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
Geneviève Evin
BioDrugs (2016) Vol. 30, Iss. 3, pp. 173-194
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Alzheimer's disease drug development pipeline: 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2017) Vol. 3, Iss. 3, pp. 367-384
Open Access | Times Cited: 358
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
Mohammad Nasb, Weichu Tao, Ning Chen
Aging and Disease (2023)
Open Access | Times Cited: 65
Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
Ivan Alić, Pollyanna Goh, Aoife Murray, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 10, pp. 5766-5788
Open Access | Times Cited: 94
An Overview of the Protective Effects of Chitosan and Acetylated Chitosan Oligosaccharides against Neuronal Disorders
Cui Hao, Wei Wang, Shuyao Wang, et al.
Marine Drugs (2017) Vol. 15, Iss. 4, pp. 89-89
Open Access | Times Cited: 75
Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design
Qin Cao, Woo Shik Shin, Henry Chan, et al.
Nature Chemistry (2018) Vol. 10, Iss. 12, pp. 1213-1221
Open Access | Times Cited: 57
BACE1 inhibitor drugs for the treatment of Alzheimer's disease: Lessons learned, challenges to overcome, and future prospects<sup>† </sup>
Arun K. Ghosh
Global Health & Medicine (2024) Vol. 6, Iss. 3, pp. 164-169
Open Access | Times Cited: 5
A review of chitosan polysaccharides: Neuropharmacological implications and tissue regeneration
Youssef Ait Hamdan, Bilal El‐Mansoury, Samia Elouali, et al.
International Journal of Biological Macromolecules (2024) Vol. 279, pp. 135356-135356
Closed Access | Times Cited: 5
Antiamyloidogenic Chemical/Biochemical-Based Designed Nanoparticle as Artificial Chaperone for Efficient Inhibition of Protein Aggregation
Nibedita Pradhan, Koushik Debnath, Suman Mandal, et al.
Biomacromolecules (2018) Vol. 19, Iss. 6, pp. 1721-1731
Closed Access | Times Cited: 41
THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASE
Cristina López López, Antonella Caputo, F. Liu, et al.
The Journal of Prevention of Alzheimer s Disease (2017), pp. 1-5
Open Access | Times Cited: 35
Experimental approaches for altering the expression of Abeta‐degrading enzymes
David A. Loeffler
Journal of Neurochemistry (2023) Vol. 164, Iss. 6, pp. 725-763
Open Access | Times Cited: 9
Role of sugar osmolytes and their nano-counterparts as inhibitors in protein fibrillation
Danish Alam, Farha Naaz, Asimul Islam, et al.
Journal of Molecular Liquids (2023) Vol. 386, pp. 122479-122479
Closed Access | Times Cited: 9
Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease
Chris G. Parsons, Gerhard Rammes
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 5, pp. 579-592
Closed Access | Times Cited: 27
Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport
Nadine Ruderisch, Daniel C. Schlatter, A. Kuglstatter, et al.
EBioMedicine (2017) Vol. 24, pp. 76-92
Open Access | Times Cited: 25
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
Myuri Ruthirakuhan, Nathan Herrmann, Ivonne Suridjan, et al.
Expert Opinion on Pharmacotherapy (2016) Vol. 17, Iss. 18, pp. 2417-2429
Closed Access | Times Cited: 20
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein‐Templated Synthesis
Vanesa Nozal, Alfonso Garcı́a-Rubia, Eva P. Cuevas, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 35, pp. 19344-19354
Open Access | Times Cited: 16
BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
Yee Jie Yeap, Nagaendran Kandiah, Dean Nižetić, et al.
Journal of Alzheimer s Disease (2022) Vol. 94, Iss. s1, pp. S159-S171
Open Access | Times Cited: 12
Recent advancements in the therapeutic approaches for Alzheimer's disease treatment: Current and future perspective
Amit Sharma, Santosh Rudrawar, Sandip B. Bharate, et al.
RSC Medicinal Chemistry (2024)
Open Access | Times Cited: 2
“Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain”
Ivan Alić, Pollyanna Goh, Aoife Murray, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 16
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease
Paul J. Bernard, Djamila Bellili, Lhassane Ismaïli
Expert Opinion on Drug Discovery (2023) Vol. 19, Iss. 1, pp. 21-32
Closed Access | Times Cited: 6
Docking Studies and Biological Evaluation of a Potential β-Secretase Inhibitor of 3-Hydroxyhericenone F from Hericium erinaceus
Diling Chen, Tianqiao Yong, Jian Yang, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 17
Rapid Identification of Tanshinone IIA Metabolites in an Amyloid-β1-42 Induced Alzherimer’s Disease Rat Model using UHPLC-Q-Exactive Qrbitrap Mass Spectrometry
Shuang Liang, Zijian Wang, Jiaqi Yuan, et al.
Molecules (2019) Vol. 24, Iss. 14, pp. 2584-2584
Open Access | Times Cited: 17
Synthesis, Molecular Docking, and Preliminary Evaluation of 2‐(1,2,3‐Triazoyl)benzaldehydes As Multifunctional Agents for the Treatment of Alzheimer's Disease
Gabriel P. Costa, Rodolfo Baldinotti, Mariana G. Fronza, et al.
ChemMedChem (2020) Vol. 15, Iss. 7, pp. 610-622
Open Access | Times Cited: 14
Gram-Scale Synthesis of a β-Secretase 1 (BACE 1) Inhibitor
Brett D. Allison, Neelakandha S. Mani
ACS Omega (2017) Vol. 2, Iss. 2, pp. 397-408
Open Access | Times Cited: 13
A molecular dynamics study of the BACE1 conformational change from Apo to closed form induced by hydroxyethylamine derived compounds
Carlos Gueto-Tettay, Joshua Zuchniarz, Yeyson Fortich-Seca, et al.
Journal of Molecular Graphics and Modelling (2016) Vol. 70, pp. 181-195
Closed Access | Times Cited: 10
Recent Progress in the Drug Development for the Treatment of Alzheimer’s Disease Especially on Inhibition of Amyloid-peptide Aggregation
Yuanyuan Liu, Lin Cong, Han Chu, et al.
Mini-Reviews in Medicinal Chemistry (2020) Vol. 21, Iss. 8, pp. 969-990
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top